ATE469886T1 - 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen - Google Patents
17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungenInfo
- Publication number
- ATE469886T1 ATE469886T1 AT03783382T AT03783382T ATE469886T1 AT E469886 T1 ATE469886 T1 AT E469886T1 AT 03783382 T AT03783382 T AT 03783382T AT 03783382 T AT03783382 T AT 03783382T AT E469886 T1 ATE469886 T1 AT E469886T1
- Authority
- AT
- Austria
- Prior art keywords
- 17beta
- inhibitor
- treatment
- hydroxysteroid dehydrogenase
- dependent diseases
- Prior art date
Links
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 title 1
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 title 1
- 239000003098 androgen Substances 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42726302P | 2002-11-18 | 2002-11-18 | |
| PCT/US2003/036203 WO2004046111A1 (en) | 2002-11-18 | 2003-11-14 | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE469886T1 true ATE469886T1 (de) | 2010-06-15 |
Family
ID=32326512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03783382T ATE469886T1 (de) | 2002-11-18 | 2003-11-14 | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7074795B2 (https=) |
| EP (1) | EP1562901B1 (https=) |
| JP (2) | JP4614770B2 (https=) |
| CN (1) | CN100374421C (https=) |
| AR (1) | AR042046A1 (https=) |
| AT (1) | ATE469886T1 (https=) |
| AU (1) | AU2003290799A1 (https=) |
| CA (1) | CA2506290C (https=) |
| CL (1) | CL2003002356A1 (https=) |
| DE (1) | DE60332862D1 (https=) |
| ES (1) | ES2345146T3 (https=) |
| MX (1) | MXPA05005360A (https=) |
| MY (1) | MY130792A (https=) |
| PE (1) | PE20040750A1 (https=) |
| TW (1) | TW200412964A (https=) |
| WO (1) | WO2004046111A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05006485A (es) | 2002-12-17 | 2005-08-26 | Schering Corp | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgeno. |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| US7851474B2 (en) * | 2005-08-02 | 2010-12-14 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| US8501940B2 (en) * | 2008-07-15 | 2013-08-06 | Hoffmann-La Roche Inc. | Tetrahydrocinnoline derivatives |
| CN103596550A (zh) * | 2011-04-25 | 2014-02-19 | 朴俊炯 | 用于预防脱发和促进毛发生长的局部施用的组合物 |
| WO2014207311A1 (en) | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1 |
| US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
| KR20160042873A (ko) | 2013-06-25 | 2016-04-20 | 포렌도 파마 리미티드 | 17.베타.-하이드록시스테로이드 탈수소효소의 억제제로서 치료적 활성 17-질소 치환된 에스트라트리엔티아졸 유도체 |
| CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
| US10626140B2 (en) | 2014-12-23 | 2020-04-21 | Forendo Pharma Ltd | Prodrugs of 17β-HSD1-inhibitors |
| HK1249504A1 (zh) | 2015-09-02 | 2018-11-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | 用作溴结构域抑制剂的吡啶酮二甲酰胺 |
| FI3634975T3 (fi) | 2017-06-08 | 2024-05-03 | Organon R&D Finland Ltd | 15-beeta-[3-propanamido]substituoitujen estra-1,3,5(10)-trien-17-onien 17-oksiimeja käytettäväksi 17-beeta-hydroksisteroididehydrogenaasien inhiboimisessa |
| EP3724178B1 (en) * | 2017-12-15 | 2024-05-01 | Inthera Bioscience AG | 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer |
| BR112021010598A2 (pt) | 2018-12-05 | 2021-08-24 | Forendo Pharma Ltd | Compostos, método para preparação de um composto e composição farmacêutica |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3586053D1 (de) | 1984-08-02 | 1992-06-17 | Labrie | Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs. |
| ES2077675T3 (es) | 1989-03-10 | 1995-12-01 | Endorecherche Inc | Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos. |
| ATE269066T1 (de) | 1989-07-07 | 2004-07-15 | Endorech Inc | Kombinationstherapie zur prophylaxe und/oder behandlung von gutartiger prostatischer hyperplasie |
| HUT60139A (en) | 1989-07-07 | 1992-08-28 | Endorecherche Inc | Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| SK139194A3 (en) | 1993-05-17 | 1995-07-11 | Endorecherche Inc | The improved antiandrogens |
| US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
| AU4801197A (en) * | 1996-09-13 | 1998-04-02 | Schering Corporation | Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors |
| TR200002784T2 (tr) | 1998-03-11 | 2000-12-21 | Endorecherche, Inc | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar |
| AR036492A1 (es) * | 2001-09-06 | 2004-09-15 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes |
| MXPA04003611A (es) | 2001-10-17 | 2004-07-30 | Schering Corp | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. |
-
2003
- 2003-11-14 WO PCT/US2003/036203 patent/WO2004046111A1/en not_active Ceased
- 2003-11-14 AU AU2003290799A patent/AU2003290799A1/en not_active Abandoned
- 2003-11-14 TW TW092131992A patent/TW200412964A/zh unknown
- 2003-11-14 CA CA2506290A patent/CA2506290C/en not_active Expired - Fee Related
- 2003-11-14 JP JP2004553612A patent/JP4614770B2/ja not_active Expired - Fee Related
- 2003-11-14 AR ARP030104210A patent/AR042046A1/es unknown
- 2003-11-14 PE PE2003001156A patent/PE20040750A1/es not_active Application Discontinuation
- 2003-11-14 EP EP03783382A patent/EP1562901B1/en not_active Expired - Lifetime
- 2003-11-14 US US10/713,828 patent/US7074795B2/en not_active Expired - Fee Related
- 2003-11-14 MX MXPA05005360A patent/MXPA05005360A/es active IP Right Grant
- 2003-11-14 ES ES03783382T patent/ES2345146T3/es not_active Expired - Lifetime
- 2003-11-14 CN CNB2003801086673A patent/CN100374421C/zh not_active Expired - Fee Related
- 2003-11-14 DE DE60332862T patent/DE60332862D1/de not_active Expired - Lifetime
- 2003-11-14 MY MYPI20034363A patent/MY130792A/en unknown
- 2003-11-14 AT AT03783382T patent/ATE469886T1/de not_active IP Right Cessation
- 2003-11-14 CL CL200302356A patent/CL2003002356A1/es unknown
-
2006
- 2006-02-24 US US11/362,217 patent/US7476681B2/en not_active Expired - Fee Related
-
2010
- 2010-03-15 JP JP2010058356A patent/JP2010138204A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2506290A1 (en) | 2004-06-03 |
| CN100374421C (zh) | 2008-03-12 |
| CN1738800A (zh) | 2006-02-22 |
| EP1562901A1 (en) | 2005-08-17 |
| JP2010138204A (ja) | 2010-06-24 |
| MY130792A (en) | 2007-07-31 |
| ES2345146T3 (es) | 2010-09-16 |
| PE20040750A1 (es) | 2004-11-06 |
| TW200412964A (en) | 2004-08-01 |
| AR042046A1 (es) | 2005-06-08 |
| US7074795B2 (en) | 2006-07-11 |
| HK1073313A1 (en) | 2005-09-30 |
| AU2003290799A1 (en) | 2004-06-15 |
| US20060148816A1 (en) | 2006-07-06 |
| US7476681B2 (en) | 2009-01-13 |
| CL2003002356A1 (es) | 2005-02-11 |
| CA2506290C (en) | 2012-04-24 |
| JP4614770B2 (ja) | 2011-01-19 |
| DE60332862D1 (de) | 2010-07-15 |
| JP2006513169A (ja) | 2006-04-20 |
| EP1562901B1 (en) | 2010-06-02 |
| US20040127503A1 (en) | 2004-07-01 |
| MXPA05005360A (es) | 2005-08-03 |
| WO2004046111A1 (en) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
| ATE344253T1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| ATE354563T1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| ATE494279T1 (de) | Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate | |
| DE60114580D1 (de) | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen | |
| ATE512163T1 (de) | Verabreichung von mitteln zur behandlung von entzündungen | |
| DE60328476D1 (de) | Medizinisches ballonsystem zur behandlung von adipositas | |
| ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
| DE602005005810D1 (de) | Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen | |
| ATE469886T1 (de) | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen | |
| DE60322451D1 (de) | 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| ATE443704T1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
| DE60236743D1 (de) | Zur behandlung androgenabhängiger krankheiten | |
| DE602004001134D1 (de) | Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit | |
| EP1651237A4 (en) | METHODS OF TREATING DERMATOLOGICAL DISORDERS | |
| DE602004022035D1 (de) | Verwendung von pthalide derivativen zur behandlung | |
| DE602004019576D1 (de) | Zur behandlung von schmerzen geeignete piperazine | |
| DE602004006118D1 (de) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER | |
| ATE457725T1 (de) | Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes | |
| DE602005016141D1 (de) | S-mirtazapin zur behandlung von hitzewallungen | |
| ATE549026T1 (de) | Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren | |
| DE60229047D1 (de) | Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit | |
| ATE482707T1 (de) | 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |